Zhongqi Capital
VC Fund
Beijing, China
Zhongqi Capital is an investment firm that offers a private equity investment management platform.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Zhongqi Capital invests in
ManufacturingAdvanced MaterialsIndustrialMedicalElectronics
Stages Zhongqi Capital invests in
Series ASeedSeries BPrivate EquitySeries D
Countries Zhongqi Capital invests in
China
Investment Focus
Industry
- Manufacturing 7 (39%)
- Advanced Materials 5 (28%)
- Industrial 4 (22%)
- Medical 3 (17%)
- Electronics 3 (17%)
Stage
- Series A 7 (39%)
- Seed 4 (22%)
- Series B 2 (11%)
- Private Equity 2 (11%)
- Series D 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Weikai High-Tech
|
Sifang Weikai High-Tech operates an intelligent Industry 4.0 production base, and its products are widely used in autos, motorbikes, rail transit, and construction machines. | Series A / Aug 03, 2026 | |
|
Sifang Weikai
|
Sifang Weikai focuses on high-end industrial decorative coatings and functional materials for high-end equipment. | Series A / Aug 02, 2026 | |
Topwell Biotech
|
Topwell Biotech is a biotechnology company offering research and development of synthetic biology technologies and biodegradable materials. | Series A / May 21, 2026 | |
| Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M / Series E / Apr 03, 2026 | ||
|
Yonggeng Technology
|
Yonggeng Technology focuses on the development and industrial application of high-end photolithography media materials. | Series A / Nov 04, 2025 | |
| Feature-Tec is a filtration and separation technology that specializes in R&D, design, manufacturing, and verification. | Private Equity / Nov 03, 2025 | ||
| NEWCCESS specializes in PCB drilling entry and backup boards and electronic new materials. It was incorporated in 1996, and its products have been exported to countries and regions, such as the U.S., Europe, Japan, South Korea, Southeast Asia, Taiwan, and more. For over 20 years, Newccess has been strategically positioned in major PCB marketslocated throughout China. Three subsidiaries were created, which are Kunshan Newccess Electronic Co., Ltd., Hunan Newccess Electronic New Materials Co., Ltd., and Yantai Newccess New Materials Co., Ltd. | Seed / Oct 21, 2025 | ||
|
Kairuis New Materials
|
Kairuis New Materials is a copper clad laminate (CCL) manufacturer specializing in the research, development, and production of high-speed CCLs, packaging substrates, and copper foil substrates. | Seed / Oct 21, 2025 | |
| Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $112.2M / Series D / Oct 09, 2025 | ||
| Photonics is a provider of optical technology and 3D vision solutions. It is a high-tech startup from Silicon Valley in the United States. It uses the world's most advanced nano-optical technology to propose a new 3D vision solution with independent intellectual property rights. The solution has the advantages of low cost, low powerconsumption, mature supply chain, etc., and is convenient for 3D visual technology to be widely applied to smart terminals, AR/VR, intelligent security, robot vision, automatic driving, automated medical and other fields. US dollar market. | Series B / Sep 15, 2025 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
Manufacturing Investors
24,696 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
Hardware VC Funds
30,945 investors
FAQ
What does Zhongqi Capital invest in?
Zhongqi Capital invests primarily in Manufacturing, Advanced Materials and Industrial startups, most often at Series A and Seed stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Zhongqi Capital last invest?
The most recent investment recorded for Zhongqi Capital closed in Aug 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
